Skip to Content

Vismodegib Dosage

Medically reviewed by Last updated on Apr 10, 2019.

Applies to the following strengths: 150 mg

Usual Adult Dose for Basal Cell Carcinoma

150 mg orally once a day until disease progression or unacceptable toxicity

-Withhold therapy for up to 8 weeks for intolerable adverse reactions until improvement or resolution.
-Treatment durations shorter than 8 weeks prior to interruptions have not been studied.

Use: Treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.


-This drug can cause embryofetal death or severe birth defects when administered to a pregnant woman.
-This drug is embryotoxic, fetotoxic, and teratogenic in animals.
-Teratogenic effects include severe midline defects, missing digits, and other irreversible malformations.
-Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating therapy.
-Advise pregnant women of the potential risks to a fetus.
-Advise females of reproductive potential to use effective contraception during and after therapy.
-Advise males of the potential risk of drug exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential.


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-This drug may be taken with or without food.
-Swallow capsules whole; do not open or crush.
-If a dose of is missed, do not make it up; resume with the next scheduled dose.

Storage requirements:
-Store at room temperature 20C to 25C (68F to 77F); excursions permitted between 15C to 30C (59F to 86F).
-Keep the bottle tightly closed to protect from moisture.


Patient advice:
-Advise patients that exposure during pregnancy can cause embryofetal death or severe birth defects.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.